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Summary
 
Major histocompatibility complex (MHC) class II molecules can present peptides derived from
two different sources. The predominant source of peptide in uninfected antigen presenting
cells (APCs) is from self-proteins that are synthesized within the cell and traffic through the
MHC class II compartment. The other source of antigen is endocytosed proteins, which in-
cludes both self- and foreign proteins. Foreign protein antigens generate adaptive immune re-
sponses, whereas self-peptides stabilize the MHC class II heterodimer on the cell surface, al-
lowing positive and negative selection of thymocytes. Therefore, self-antigens play an
important normal role in shaping the T cell receptor repertoire as well as a pathological role in
autoimmunity. To determine whether processing and presentation of self-antigens by MHC
class II molecules differs depending on whether the antigen is supplied through synthesis within
the cell or by endocytosis, we used a T cell clone against an E
 
a
 
 peptide presented by I-A
 
b
 
 to
show that processing through these two routes can differ. We also show that mice can be toler-
ant to the epitope formed through the endogenous route, but responsive to the epitope that
can be formed through endocytosis. This suggests that negative selection occurs primarily
against antigens that are synthesized within the APC, and that endocytosed self-antigens could
serve as autoantigens. Finally, we also demonstrate that lipopolysaccharide-activated B cells are
defective for uptake, processing, and presentation of this self-antigen, and that this correlates
with the increased expression of the costimulatory molecules B7.1 and B7.2. This may provide
a model for studying the onset of an autoimmune response.
 
P
 
eptides that are presented on MHC class II molecules
are derived from two different sources, and they serve
two different functions. Under normal conditions, most
MHC class II molecules are occupied by peptides derived
from antigens that are synthesized within the APC itself.
Peptides that are derived from endogenously synthesized
proteins traffic through the endocytic compartment and are
primarily derived from other MHC class I and class II mol-
ecules (1). These self-peptides allow stable expression of the
MHC class II molecules on the cell surface (2), so that these
complexes can be used for positive and negative selection
of thymocytes (3). The other protein source for MHC class
II associated peptides are proteins that must be internalized
via endocytosis. Pathogens provide a source of antigen
which must be endocytosed, and peptides of this type are
also presented by MHC class II molecules to naive T cells,
so that the organism can mount an appropriate adaptive
immune response against the pathogen.
This implies that two types of antigen can be loaded
through the endocytic pathway. The first type is pathogen
derived, whereas the second is endocytosed self-antigens.
This raises the question of whether processing of proteins
that gain access to the MHC class II compartment after en-
dogenous synthesis differs from processing of the same pro-
teins which gain access to the MHC class II compartment
through endocytosis. Although some data exists that sug-
gests that processing of endogenously synthesized and en-
docytosed exogenous antigen may differ (4), essentially no
data exist that specifically address this question. Such differ-
ences could have important implications both for positive
and negative selection of the TCR repertoire and for au-
toimmunity.
Studies in recent years have focused on identifying the
compartment(s) in which antigen processing and peptide
loading onto MHC class II molecules occurs, referred to as
the MHC class II compartment (MIIC)
 
1
 
 or the class II
loading vesicle (CIIV) (5, 6). From these studies and others
examining mechanisms of MHC trafficking, proteolysis of
the MHC class II invariant chain (Ii), and peptide loading
has emerged a more complete model for MHC class II traf-
 
1
 
Abbreviations used in this paper:
 
 CIIV, class II loading vesicle; Ii, invariant
chain; MIIC, MHC class II compartment.
  
1404
 
Processing of Autoantigenic Peptides Breaks Self-tolerance
 
ficking. MHC class II molecules are transported as a com-
plex with Ii to an endosomal compartment. Ii directs this
localization and retains the complex in this compartment
until Ii is cleaved to a form called the class II Ii peptide
(CLIP) that is still bound in the groove of the MHC mole-
cule but is no longer anchored to the membrane (7–9). At
this point, Ii can still prevent binding of other peptides to
MHC class II, but can no longer direct its trafficking.
MHC class II itself, however, contains signals that direct it
to the endocytic compartment (10). These signals may then
direct the localization of MHC class II to MIIC/CIIV, per-
haps even directing its formation (11). In the CIIV, DM
can catalyze the removal of CLIP and the binding of pep-
tide (12). Rapid transport of the MHC–peptide complex to
the cell surface then occurs. This rapid transport is sug-
gested by the kinetics of transport of SDS stable MHC–
peptide complexes from CIIV to the cell surface (5), and
the fact that large intracellular pools of MHC class II are
not detected in early endosomal compartments under nor-
mal conditions (13). Rapid transport to the cell surface may
preclude further processing of the MHC–peptide complex
under the variable conditions potentially available along the
endosomal pathway.
In any case, the finding that endogenously synthesized
antigen is presented by MHC class II has raised the ques-
tion of whether endogenous and endocytosed exogenous
antigens are processed and loaded onto MHC class II mole-
cules in the same form (5, 14). A study using the antibody
Y-A
 
e
 
, which can detect a specific MHC–peptide complex
(I-A
 
b
 
 
 
1
 
 E
 
a
 
 52–68), shows that this complex forms from
endogenously synthesized molecules in the MIIC (15), as
can the same epitope from exogenously derived peptides.
Thus, what appears to be the same MHC–peptide complex
can form in the same specialized compartment. However,
it is not clear from this analysis if the same product is pro-
duced, as T cell recognition of the Y-A
 
e
 
 epitope was not
determined. It is not yet clear, furthermore, that endoge-
nously synthesized protein antigens have access to all of the
antigen-processing compartments. To examine this ques-
tion, we prepared T cell clones by immunization of
C57BL/6J mice that express I-A
 
b
 
 but lack E
 
a
 
. We also im-
munized B10.A(5R) and B10.A(3R) mice that are similarly
I-A
 
b
 
 positive but possess the E
 
a
 
 chain and express the Y-A
 
e
 
epitope (16, 17). These studies illustrate three important
points. First, that endocytosed antigen is processed dis-
tinctly from endogenously synthesized antigen. Second,
that tolerance exists to endogenously synthesized antigen
but not to antigen internalized by endocytosis. Third, that
the ability of APCs to take up and present antigen is recip-
rocally regulated with the induction of costimulatory mole-
cules, which may serve to prevent autoimmunization of
existing potentially autoreactive T cells.
 
Materials and Methods
 
Peptides.
 
The peptides were synthesized as previously de-
scribed (16), purified by HPLC, and checked for accuracy by
mass spectroscopy and amino acid analysis by the W.M. Keck
 
Biotechnology Resource Center (Yale University, New Haven,
CT). The sequence of E
 
a
 
 52–68, the longest peptide used here,
is: A S F E A Q G A L A N I A V D K A, whereas peptide Ea
52–66 is truncated two amino acid residues (-KA) at its COOH-
terminus.
 
Mice.
 
C57BL/6J(B6), B10.A(3R) (3R), B10.A(5R) (5R), or
107.1 (B6–I-E transgenic) mice were used in the experiments
shown here. B6 and 5R mice were obtained from The Jackson
Laboratory (Bar Harbor, ME). 3R mice were bred and main-
tained within our own animal facility. 107.1 mice were obtained
from Richard Flavell (Yale University).
 
T Cells.
 
E
 
a
 
6, the T cell clone used in these experiments, was
raised by footpad immunization of C57BL6/J (B6) mice with 30
 
m
 
g of E
 
a
 
 52–68 in CFA. After 8 d, popliteal lymph nodes were
removed and placed in bulk culture with 10 
 
m
 
g/ml E
 
a
 
 52–68,
 
z
 
10 U/ml of IL-2 and 10% FCS. After three weekly restimula-
tions the cultures were cloned by limiting dilution. Clones were
expanded from plates that contained much less than 1 cell/well
by Poisson distribution. Two of the clones were subcloned, but
parental clones were found to give better responses, so they were
used for these studies. Anti-V
 
b
 
 FACS
 
Ò
 
 staining and anti-V
 
a
 
 PCR
analysis confirmed that the parental lines were monoclonal (Viret,
C., unpublished data). The clones were maintained by restimulation
every 2 wk with fivefold excess irradiated (2,000 rads) or mitomy-
cin C–treated (50 
 
m
 
g/ml; Boehringer Mannheim, Indianapolis, IN)
C57BL6/J spleen cells, 3 
 
m
 
g/ml E
 
a
 
 52–68 or E
 
a
 
 52–66, 
 
,
 
5 U/ml
IL-2, and 5% FCS. Unless otherwise stated, all assays and cultures
were done in Click’s medium (Irvine Scientific Co., Santa Ana, CA)
containing 5% FCS, 3 
 
3 
 
10
 
2
 
5 
 
M 2-ME, 2 
 
3 
 
10
 
2
 
4 
 
M 
 
l
 
-glutamine,
and antibiotics. The T cell hybridoma, 1H3.1, has been previ-
ously described (16). Finally, to examine tolerance to E
 
a
 
52–68
and E
 
a
 
52–66, we immunized 3R, 5R, and B6 mice with either
peptide and measured their responses to the immunizing and the
alternative form of the peptide. These responses were inhibitable
with Y-A
 
e
 
 monoclonal antibodies added to the cultures.
 
T Cell Clone and Hybrid Assays.
 
All proliferation assays were
set up using 2 
 
3 
 
10
 
4
 
 cloned T cells/well in 96-well plates. 2–3 
 
3
 
10
 
5
 
 irradiated or mitomycin C–treated splenocytes/well were
used as APCs. All proliferation assays were cultured for 40–48 h
at 37
 
8
 
C, and then pulsed with 1 
 
m
 
Ci per well [
 
3
 
H]thymidine (6.7
Ci/mmol; Amersham Corp., Arlington Heights, IL) for 6–12 h.
The plates were then harvested and counted. Hybrid assays, mea-
suring IL-2 production by CTLL assay, were performed as de-
scribed (16). All T cell and hybrid assays were performed in du-
plicate or triplicate. Each experiment shown is representative of
multiple assays. For LPS assays, 4 
 
3 
 
10
 
6
 
 splenocytes/ml were cul-
tured with 10 
 
m
 
g/ml LPS (Difco Labs., Detroit, MI) for 24 h and
were then harvested, irradiated (2,000 rads), washed, counted,
and cultured with peptides and T cells.
 
Antibodies.
 
The antibodies used in these experiments were
Y-A
 
e
 
 (17), the anti–I-A
 
b
 
 antibody Y3JP (18), and the anti–I-E
antibody Y17 (19). FACS
 
Ò
 
 (Becton Dickinson, Mountain View,
CA) staining and analysis was performed as previously described
(16). Y-A
 
e
 
 was detected using FITC-labeled Fc-specific goat
anti–mouse IgG (1:500; Sigma Chemical Co., St. Louis, MO).
The anti-CD28 antibody 37N51was used to provide costimula-
tion in some experiments. Culture supernatant was added to T
cells and APCs at the optimal dilution of 1:30 (final concentra-
tion) before the addition of the cross-linking antibody, goat anti–
hamster IgG (Caltag Labs., San Francisco, CA) at 1 
 
m
 
g/ml.
 
Antibody Stimulation.
 
In mAb stimulation assays, mAbs were
added to the APCs as purified mAb or tissue culture supernatants
30–60 min before the addition of the T cells. 
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Inhibitors of Antigen Processing.
 
100 
 
m
 
M chloroquine, 100 
 
m
 
M
primaquine, or 1.5 mM ammonium chloride was used to block
antigen processing. The inhibitors were added to irradiated
splenic APCs at twice the concentration listed above for 30–45
min at 37
 
8
 
C before dilution to the concentration listed above by
peptide antigen. The APCs were then cultured overnight in the
presence of the inhibitors and the peptide before we washed the
APCs and added T cells. Anti-CD28 and the cross-linking anti-
body goat anti–hamster were added to all wells to provide co-
stimulation. The APCs, having been irradiated on the previous
day, probably would not be able to provide the necessary costim-
ulation for the T cells. The APCs were treated overnight because
long pulses with E
 
a
 
 52–68 were necessary to obtain a strong pro-
liferative response from E
 
a
 
6.
 
Fixation.
 
APCs were fixed at 
 
,
 
3
 
 3 
 
10
 
7
 
 cells/ml in 0.2%
paraformaldehyde for 5 min at room temperature. The cells were
then diluted threefold with 0.2 M glycine in Click’s medium,
pelleted, and washed two times with complete media. Anti-
CD28 was added in combination with the cross-linking antibody
goat anti–hamster to provide costimulation, as described below.
 
Purification of I-E Protein.
 
Whole I-E protein was isolated as
described for I-A
 
b
 
, from 100 (B6 
 
3 
 
C3H) F2 mice (provided by
Richard Flavell). In brief, for this procedure a Y17 sepharose col-
umn was added between a nonspecific control column and a Y-A
 
e
 
column. I-E was eluted from the Y17 column with high pH
buffer, and neutralized immediately with 1 M Tris, pH7. This
material was dialyzed at 4
 
8
 
C against PBS, and stored at 4
 
8
 
C until
use in the assays described above.
 
Immunization of B6 Mice against I-E.
 
To generate an antigen-
specific, receptor-mediated uptake mechanism to enhance pre-
sentation of limited quantities of I-E protein, B6 mice were
repeatedly immunized with B6/I-E transgenic (strain 107.1, pro-
vided by Richard Flavell) splenocytes. Before experiment 1,
which is shown in Fig. 8, two B6 mice were immunized intra-
peritoneally with 2 
 
3 
 
10
 
7
 
 107.1 splenocytes. After 5 d the mice
were reimmunized intravascularly via retroorbital sinus with 10
 
7
 
107.1 splenocytes. After another 4 d, a B6 spleen was removed
from one of the immunized animals, irradiated with 1,000 rads to
maintain the APC function of B cells, and used for experiment 1
(Fig. 8, 
 
A
 
 and 
 
B
 
). After 
 
z
 
1 wk, the other mouse was reimmu-
nized intravascularly with 2 
 
3 
 
10
 
7
 
 107.1 splenocytes, except this
time the 107.1 cells were treated with LPS for 20 h before injec-
tion. After another 4 d the B6 spleen was removed, irradiated
(1,000 rads), and used for experiment 2 (Fig. 8 
 
C
 
). Spleen from
unimmunized B6 was also used.
 
Results
 
Clone E
 
a
 
6 Does Not Respond to 3R APCs unless E
 
a
 
 52–68
Peptide Is Added.
 
To compare processing of endogenously
synthesized antigen with the processing of exogenously
supplied antigen, T cell clones were raised in C57BL/6J
(B6) mice by immunization with a synthetic peptide de-
rived from the sequence of MHC class II E
 
a
 
 chain residues
52–68. B6 mice express the MHC class II molecule I-A
 
b
 
,
but do not express the peptide donor molecule I-E. This
peptide was chosen because it is known to be presented by
the MHC class II molecule I-A
 
b
 
 when I-E is also synthe-
sized within the cell (1). Additionally, a monoclonal anti-
body, Y-A
 
e
 
, specifically recognizes this MHC–peptide
complex, allowing its easy detection (1, 17).
Figure 1. Ea6 responds to Ea52–68 presented by I-Ab but not to en-
dogenous ligand on B10.A (3R), whereas control hybrid 1H3.1 responds
to both exogenous and endogenous ligand. (A) The proliferative response
of the T cell clone Ea6 to APCs which did (3R) or did not (B6) express
endogenous ligand, in the presence or absence of the peptide Ea52–68.
The ability of the monoclonal antibody Y-Ae, which also recognizes the
I-Ab–Ea peptide complex, to block the response of the clone is also
shown. (B) The response of 1H3.1 was measured by culture of 105 hy-
brids with 2 3 105 splenocytes along with the indicated antibodies and
peptide. Culture supernatant was removed after 20 h and tested for the
presence of IL-2 using the IL-2–dependent cell line CTLL. In A, the re-
sponse to B6 splenocyte 1 the synthetic peptide Ea52–66 is shown. Re-
sponses to Ea52–68 were similar. In B, the response of 1H3.1 cells to the
endogenous ligand on 3R cells is also shown. No synthetic peptide was
added since 1H3.1 responds to the endogenous ligand. The antibodies
were added to the culture wells to show that the response of 1H3.1 is re-
stricted by I-Ab and is also blocked by Y-Ae. Y3P is an anti–I-Ab anti-
body. Y-Ae did not block the response of a control clone D10 (data not
shown), which recognizes an I-Ab ligand different from that recognized
by Y-Ae. Y-17, an anti–I-E antibody, does not block the response of ei-
ther 1H3.1 or Ea6 (data not shown). (C) Flow cytometric staining with
the antibody Y-Ae. Staining of B6 and 3R splenocytes in the presence of
a titration of the peptide Ea52–68 is compared.1406 Processing of Autoantigenic Peptides Breaks Self-tolerance
All of the clones responded to synthetic peptides and
were restricted by I-Ab as shown by antibody blocking ex-
periments; their response was also blocked by the antibody
Y-Ae (Fig. 1 A). Surprisingly, none of the clones responded
to the I-Ab–Ea peptide complex presented on 3R spleno-
cytes that express I-E molecules and the Y-Ae epitope (Fig.
1 B). Although the experiment shown here has an unusu-
ally strong response of Ea6 to 3R APCs in the absence of
synthetic peptide, this response was weak relative to the re-
sponse of Ea6 to APCs plus synthetic peptide. Typically,
this response was no greater than the background response
of Ea6 to B6 APCs (see Fig. 5). This suggested that pro-
cessing of endogenously synthesized antigen differed from
processing of exogenously supplied antigen. It may be that
the synthetic peptide which was added to the culture had
been processed to a shorter form that is required for stimu-
lating the Ea6 clone. A control hybrid was also raised by
immunization of B6 mice with the peptide Ea52–68; this
hybrid is also restricted by I-Ab, and blocked by Y-Ae, but
this hybrid also responded to the endogenously synthesized
and processed ligand on 3R spleen cells (Fig. 1 B).
The Presence of Too Much or Too Little Ligand Can Not Ex-
plain the Lack of Response of Ea6 to 3R Cells. The possibility
that either too much or too little ligand was responsible for
the lack of response of the cloned T cell line Ea6 to the
endogenously generated ligand was ruled out in several ini-
tial experiments. Since the Y-Ae antibody recognizes the
synthetic Ea peptide bound to I-Ab as well as the endoge-
nously generated complex, FACSÒ staining with Y-Ae was
used to compare the level of ligand created by addition of
the synthetic peptide to the level of endogenous ligand.
Fig. 1 C shows that even at doses of synthetic peptide suffi-
cient to give plateau stimulation of Ea6 (10 mg/ml), the
staining with Y-Ae was much lower than that on 3R sple-
nocytes. Therefore, the lack of response of Ea6 was not
due simply to overly low levels of the ligand on the APCs.
However, too much ligand can suppress the response of
T cell clones, as is seen in Fig. 2 A. As shown in Fig. 1 A,
Ea6 T cells responded similarly to synthetic peptide added
to B6, which does not express the endogenous ligand, and
3R, which does express the endogenous ligand. Dose–
response curves of the response of Ea6 to peptide on B6 or
3R completely overlap (data not shown). Since addition of
antigen allowed the clones to respond, their lack of re-
sponse to the endogenously synthesized protein could not
be explained by the phenomenon of high antigen dose sup-
pression.
The Clones Were Not Raised against a Contaminant in the
Peptide Preparation. The possibility that the clones were
responding to a contaminant in the peptide preparation was
examined. The peptide, Ea52–68, was synthesized on sev-
eral separate occasions, purified by HPLC, and checked for
accuracy by amino acid analysis and mass spectroscopy.
The main species was determined to have the correct se-
quence, but, minor contaminants were still present. How-
ever, blocking of the response of the clones by the anti-
body Y-Ae suggests that they are specific for the Ea
peptide, since this antibody specifically recognizes this pep-
tide when bound to I-Ab (Fig. 1, A–C). Additional HPLC
purifications enhanced the response of Ea6, indicating that
Ea6 does respond to the correct peptide and not to a con-
taminant (not shown).
Ea6 Required a Truncated Ea Peptide which Was Not Pro-
cessed from the Endogenous Protein. We next asked if Ea6
responded to a different length of the Ea peptide than did
1H3.1. As shown in Fig. 2 A, 10-fold less Ea52–66 than
Ea52–68 was required to give the same stimulation of
Ea6, whereas 1H3.1 responded equally to both peptides
(Fig. 2 B). Further truncation on either end of the peptide
decreased stimulatory capacity for Ea6, whereas 1H3.1
could respond to a nonapeptide epitope Ea56–64 (Fig. 2 A
and data not shown). This suggested that Ea6 required
processing of Ea52–68 to Ea52–66 in order to respond.
To investigate this further, two experiments were per-
formed to determine whether Ea6 requires that Ea52–68
Figure 2. The response of Ea6 and control hybrid 1H3.1 to length
variants of Ea peptide. (A) The proliferative response (measured by in-
corporation of [3H]thymidine) of Ea6 to two synthetic length variants of
the Ea peptide, Ea52–68 and Ea52–66. (B) The response of control hy-
brid 1H3.1 to the same Ea peptide length variants. The response of
1H3.1 was measured by IL-2 production that was detected by the prolif-
erative response of the IL-2–dependent cell line CTLL.1407 Barlow et al.
be processed to a shorter form. The first is shown in Fig. 3.
Splenocytes were either irradiated (designated live), or
fixed in paraformaldehyde before addition of the synthetic
peptides. Ea6 could only respond to Ea52–68 when pre-
sented by live APCs that could still endocytose and process
the peptide. The peptide Ea52–66 did not need processing
to stimulate Ea6, since it could be presented by either live
or formaldehyde-fixed APCs (Fig. 3 A). The control hy-
brid, 1H3.1, could respond to both peptides on either live
or fixed cells, showing that neither peptide required pro-
cessing to stimulate 1H3.1, and that Ea52–68 could bind
to I-Ab on fixed cells (data not shown). Flow cytometric
staining with Y-Ae, shown in Fig. 3 B, confirmed that
loading of Ea52–68 onto I-Ab on live or fixed cells was not
less than loading of the other two peptides. Thus, the in-
ability of Ea6 to respond to the longer peptide on fixed
cells could not be explained as an inability of this peptide to
bind I-Ab on fixed cells. This supported the hypothesis that
Ea52–68 was the endogenous ligand, to which only 1H3.1
could respond, and that Ea52–66 was not produced from
the endogenously synthesized and processed protein.
We next asked whether drugs that block the acidification
of the endocytic pathway and are known to inhibit pro-
cessing of exogenous peptides and proteins could also in-
Figure 3. Ea6 responds to Ea52–66 and Ea52–68 on live APCs, but does not respond to the longer peptide presented by fixed APCs. (A) Live APCs.
The proliferative response of Ea6 to length variants of the Ea peptide presented on irradiated splenic APCs that could still take up antigen for processing
(Live). (B) Fixed APCs + cross-linked anti-CD28. A similar proliferation assay, except the APCs were paraformaldehyde fixed splenocytes, which could
no longer take up and process antigen. Anti-CD28 and goat anti–hamster IgG (Caltag Labs.) were added to the experiment in B to provide costimulatory
signals, which could not be provided by the fixed APCs. C shows Y-Ae flow cytometric staining of live APCs after peptide loading, and D shows Y-Ae
staining of APCs that were fixed before loading peptides. Y-Ae detects the loading of Ea peptides on I-Ab. The mean fluorescence intensity of unstained
cells was subtracted from all samples to give a shift in mean fluorescence intensity. The mean fluorescence intensity of B6 APCs stained with Y-Ae in the
absence of added Ea peptide was subtracted from the mean fluorescence intensity of samples stained after peptide loading in order to control for back-
ground staining by Y-Ae, which does not normally stain B6 APCs. The staining was performed in triplicate.1408 Processing of Autoantigenic Peptides Breaks Self-tolerance
hibit the response of Ea6 to Ea52–68. APCs were treated
for 30 min with the lysosomotropic agents chloroquine or
ammonium chloride. Peptides were then pulsed onto the
APCs overnight in the presence of the inhibitors. The
APCs were finally washed and added to T cells in the pres-
ence of cross-linked anti-CD28, added to all wells to pro-
vide costimulation needed for T cell responses. Fig. 4
shows that both chloroquine and ammonium chloride in-
hibited presentation of Ea52–68 to Ea6, but could not
completely block presentation of Ea 52–66 to Ea6 or pre-
sentation of either peptide to 1H3.1. These inhibitors de-
creased the overall proliferation of the clones to all of the
peptides. However, the background response was also
lower, so the fold response was actually higher in the pres-
Figure 4. Comparison of the responses of Ea6 and control 1H3.1 to
Ea52–66 and Ea52–68 in the presence or absence of inhibitors of pro-
cessing. (A) Proliferative responses of Ea6. (B) IL-2 production by 1H3.1
as measured by CTLL assay. Both panels show the fold response to Ea
peptides loaded onto APCs in the presence of inhibitors of processing as a
percentage of the fold response to Ea peptides loaded onto APCs in the
absence of inhibitors of processing. Some of the responses shown are
.100%, because the background response was lower in the samples in
which inhibitors of processing were included. Thus, although maximum
cpm achieved in the presence of the inhibitors was lower than in the ab-
sence of the inhibitors, the fold response was greater in the presence of
the inhibitors. h, n, chloroquine; j,m, ammonium chloride. h, j,
Ea52–66; m, n, Ea52–68.
Figure 5. Anti–I-Ab mAb created an I-E–dependent epitope for Ea6
on splenocytes. The proliferative response of Ea6 to mAb treatment of
APCs which did not (A) or did (B and C) express endogenous ligand is
shown. No synthetic peptide was added to this experiment. 107.1 is a B6
mouse which expresses an Ea transgene. The APCs were cultured with
mAb for 30–60 min at 378C and then T cells were added. The mixture
was then cultured for 48–60 h and pulsed overnight with 1 mCi per well
of [3H]thymidine, as with a proliferation assay to test the response to syn-
thetic peptide.1409 Barlow et al.
ence of inhibitors. The flow cytometric analysis with Y-Ae
(data not shown) confirmed that loading of the peptides
onto I-Ab was equivalent in the presence and absence of
the inhibitors. Thus, the lack of response of Ea6 to the
longer peptide was not due to a decrease in the ability to
load the longer peptide in the presence of the inhibitors.
Therefore, Ea6 appeared to respond selectively to Ea52–
66, and could not recognize the naturally processed peptide
Ea52–68 in the absence of further processing.
Forced Internalization of I-Ab on 3R or I-E Transgenic Spleen
Cells Created a Ligand for Ea6. The ability of live 3R
splenocytes to create the ligand for Ea6 from the synthetic
peptide Ea52–68 (see Fig. 1 A) suggested that these APCs
may also be capable of creating the correct ligand from the
endogenously synthesized proteins if these proteins were
processed in the correct compartment(s). To test this hy-
pothesis, anti–I-Ab antibodies were added to 3R or control
B6 splenocytes before addition of Ea6 in an attempt to
force the recycling and reprocessing of I-Ab–peptide com-
plexes. The presence of anti–I-Ab antibodies allowed Ea6
to respond to the endogenous ligand in the absence of
added exogenous synthetic peptide. This response was spe-
cific for the Ea peptide–I-Ab complex, since the clones
only responded when both I-Ab and I-E were expressed in
the APCs, either as 3R or as a transgenic Ea chain in the
B6/I-E transgenic line called 107.1 (Fig. 5, A–C). Several
anti–I-Ab antibodies including both culture supernatants
and purified mAb could mediate this response (data not
shown), indicating that the response was not due to con-
tamination by other potentially stimulatory antibodies. Ad-
ditionally, cultured bone marrow dendritic cells from 3R
mice only stimulated Ea6 after treatment with anti–I-Ab
antibody culture supernatants (data not shown).
The possibility that the antibodies lead to proliferation of
Ea6 by stimulating the APCs to express costimulatory sig-
nals was tested and ruled out. Providing costimulation in
conjunction with the endogenous ligand, by using 3R LPS
blasts, or cross-linked anti-CD28 with 3R APCs, was not
sufficient to cause proliferation of Ea6 (data not shown).
Thus, the most likely explanation for the ability of the
anti–I-Ab antibodies to cause proliferation of Ea6 to en-
dogenous ligand was that the antibodies force internaliza-
tion of I-Ab and thus allow reprocessing of the ligand.
APCs Generated the Epitope for Ea6 from Whole I-E Protein
Added Exogenously. APCs were capable of generating the
epitope required for the Ea6 response from both exoge-
nously added synthetic peptide and endogenously gener-
ated peptide–MHC complexes that were forced to recycle.
Thus, it seemed likely that the lack of response of Ea6 to
the unmanipulated endogenous ligand was due to an in-
ability of the complex or individual components to traffic
through the compartment required to generate the ligand
for Ea6. Alternatively, APCs may have been able to gener-
ate the ligand for Ea6 from the peptide Ea52–68, but they
may not have been able to generate the ligand for Ea6
from whole protein. This possibility was actually already
partially excluded. As discussed in the preceding section,
the APCs could generate the ligand for Ea6 from the en-
dogenous ligand when it was forced to recycle. In this case,
the APC was able to perform all of the required processing
steps. However, the antibody-forced recycling is an artifi-
cial system and did not necessarily indicate that whole anti-
Figure 6. APCs can process whole I-E protein into the epitope re-
quired for Ea6 response when the protein was added exogenously. The
response of Ea6 and 1H3.1 to whole I-E protein is shown. Fig. 8 B
shows the control response to Ea52–66 peptide. Two independent ex-
periments are shown for Ea6. I-E was obtained by immunoaffinity purifi-
cation from (B6 3 C3H)F2 splenocytes using the anti–I-E antibody Y17.
Some of the B6 mice used for APCs in this experiment were immunized
with splenocytes from the B6, I-E transgenic strain 107.1 in order to try
to expand I-E–specific B6 B cells to enhance the efficiency of presenta-
tion of the whole I-E protein. The data shown for experiment (Expt.) 1
in A and B are from cultures that had APCs from mice immunized twice
with fresh 107.1 splenocytes (see text for details of immunization). The
data shown for experiment 2 in A and B are from cultures that had APCs
from unimmunized mice. Note that in experiment 1, this immunization
protocol did not enhance I-E presentation over that seen using APCs
from unimmunized mice. The data shown for experiment 2 in C are
from cultures that had APCs from mice immunized a third time, intravas-
cularly, with 107.1 LPS blasts. Splenocytes from the immunized mouse
were used as APCs 4 d after the last immunization. No additional exoge-
nous antigen was needed at this time to stimulate a response by Ea6. none,
without I-E antigen, but with Ea6 T cells and APCs from immunized B6
mice.1410 Processing of Autoantigenic Peptides Breaks Self-tolerance
gen added exogenously would gain access to the compart-
ment(s) required to generate the epitope for Ea6. Therefore,
it was of interest to determine whether APCs could process
the whole I-E protein to the epitope required for Ea6
stimulation when the protein was added exogenously.
I-E was purified from (C57BL/6J 3 C3H) F2 mice by
immunoaffinity chromatography using the anti–I-E anti-
body Y17. Fig. 6 A shows that splenic APCs processed the
whole I-E molecule into an epitope that Ea6 could recog-
nize. The response was very weak compared with the re-
sponse to synthetic peptide (Fig. 6 B); however, 1H3.1
makes an even weaker response to the exogenous I-E pro-
tein. The weak response of 1H3.1 to the whole protein in-
dicated that the weak response of Ea6 was due to low con-
centrations of the antigen and not to differences in the
ability of APCs to create the longer versus the shorter pep-
tide. The response of both Ea6 and 1H3.1 to the whole
protein was weaker than the response to the peptide if the
response was plotted against the micromolar concentration
of antigen rather than its mass. This was not unexpected as
far fewer steps are required to generate a T cell epitope
from a peptide than to generate a T cell epitope from
whole protein.
To enhance the efficiency of presentation of the limited
quantities of whole I-E protein available, an attempt was
made to obtain APCs with the ability to take up the anti-
gen specifically. To accomplish this, B6 mice were repeat-
edly immunized with splenocytes from the mouse strain
107.1, which, as discussed earlier, is a B6 mouse with an I-E
transgene. Before experiment 1, shown in Fig. 6, B6 mice
were immunized intraperitoneally with 2 3 107 107.1 sple-
nocytes. After 5 d the mice were reimmunized intravascu-
larly via the retroorbital sinus with 107 107.1 splenocytes.
After another 4 d, a B6 spleen was removed from one of
the immunized animals, irradiated with 1,000 rads to main-
tain the APC function of B cells, and used for experiment 1
in Fig. 6. APCs from unimmunized mice were also used
(data not shown), but no significant difference in the ability
to present I-E protein or peptide was noted in experiment
1. After z1 week, another mouse was reimmunized with 2 3
107 107.1 splenocytes, except that this time the 107.1 cells
were treated with LPS for 20 h before injection. After an-
other 4 d, the B6 spleen was removed and used for the ex-
periment shown in Fig. 6 C (the response to APCs from
unimmunized mice is shown for experiment 2 in Fig. 6, A
and B). Interestingly, Ea6 responded to these APCs even
without the addition of peptide or protein antigen (Fig. 6 C).
The APCs must still have been presenting antigen that was
taken up and processed from the 107.1 splenocytes. The
caveat to the experiments shown in Fig. 6, A and B, is that
the preparation of purified I-E may contain undetectable
peptide species. However, the ability of APCs from B6
mice immunized with I-E expressing splenocytes to stimu-
late Ea6 suggested that APCs could process the whole I-E
molecule to the epitope required to activate Ea6.
These data suggest that bona fide mechanisms of antigen
uptake, such as the surface Ig receptors of B cells, can lead
to the generation of the epitope required for Ea6 activa-
tion. Importantly, this indicates that the MHC class II
epitopes generated from endogenously synthesized antigen
can be different than epitopes that can be created from ex-
ogenously provided, endocytosed antigen.
Responses of 3R and B6 Mice to Priming with Ea52–68 and
Ea52–66 Peptides. To determine whether B10.A(3R)
mice fail to induce tolerance to Ea52–66, 3R mice that ex-
press the endogenous Y-Ae ligand (I-Ab 1 Ea52–68) or
control B6 mice (I-Ab only) were immunized with either
Ea52–66 or Ea52–68. Fig. 7 A shows that despite the fact
that 3R mice express large quantities of the Y-Ae epitope
(I-Ab 1 Ea52–68), they are still able to respond to the
peptide Ea52–66. These mice, as expected, do not make a
response to the Ea52–68 peptide (Fig. 7 B). This peptide,
although processed efficiently in vitro to Ea52–66, may
not be processed efficiently enough in vivo to prime a re-
sponse to Ea52–66 in 3R mice. Fig. 7, C and D, shows
that, as expected, B6 mice can respond to either Ea52–68
or Ea52–66. Thus, 3R (and 5R; data not shown) mice are
tolerant to Ea52–68 but are not tolerant to Ea52–66. The
response of 3R mice to Ea52–66 was inhibitable by Y-Ae,
proving that it involved the same epitope that was recog-
nized by Ea6 (Fig. 8); it was also shown to be mediated by
CD4 T cells (data not shown).
One implication of the above results is that autoantigen
processing is likely to occur only when an autoantigen is
acquired from the exogenous milieu and not from altered
processing of endogenous proteins in APCs, as central tol-
erance exists to such proteins. Autoimmune disease could
only result from the uptake and processing of extracellular
antigen, as happens in various disease models. To test this
hypothesis, we carried out the following experiments.
Cells Rendered Costimulator Positive Cannot Take Up and/
or Process Antigen. In the experiment shown in Fig. 9, sin-
gle cell suspensions of spleen were cultured for 24 h with
10 mg/ml LPS in order to induce costimulatory molecules.
In this experiment, macrophages would be depleted by
overnight culture on tissue culture–treated plastic, but den-
dritic cells would dissociate from the plastic after overnight
culture (20). The cultures were subsequently harvested, ir-
radiated, and washed before addition to peptide and T cells.
The harvested APCs should have been primarily B cells
with some dendritic cells. The peptide Ea52–68, which re-
quires processing to stimulate Ea6, cannot be presented by
splenic LPS blasts. The control peptide, Ea52–66, is pre-
sented to Ea6 by LPS blasts, thus indicating that the lack of
response to the longer peptide is not due to a non-specific
toxic effect of LPS. Additionally, the lack of response to
Ea52–68 presented by LPS blasts is not due to a decrease in
the ability of this peptide to bind to surface MHC class II,
since this peptide is presented to the control processing-
independent hybrid 1H3.1 (Fig. 9 B). Y-Ae staining of
both of these peptides loaded onto LPS blasts is also com-
parable (Fig. 9 C).
This general rule of reciprocal regulation of antigen pro-
cessing and the ability to costimulate T cell growth was
further tested by a time course experiment in which the
ability of APCs to present processing-independent (Ea52–1411 Barlow et al.
66) versus processing-dependent (Ea52–68) antigen is
compared at various times after treatment with LPS. APCs
were treated with LPS for 0 or 4 h. After 4 h, the LPS was
washed out and the APCs were incubated for the indicated
time period before addition of antigen. Antigen was then
added for 2 h before the APCs were washed, irradiated,
and added to culture wells with T cells or hybrids. The in-
cubations on tissue culture–treated plastic would be ex-
pected to deplete the splenocytes of adherent cells (mac-
rophages and dendritic cells), so the APCs studied in this
experiment were primarily B cells (20).
Fig. 10 A shows that presentation of Ea52–66 to Ea6
peaks at 8 h. Presentation of the processing-dependent
peptide Ea52–68 to Ea6 is greatly decreased at this time
(Fig. 10 B). In Fig. 10 C we show flow cytometric analysis
of the expression of the costimulatory molecule B7-2 at
various time points after LPS stimulation. Expression of this
molecule also peaks at 8 h with this protocol of LPS treat-
ment. Thus, there is a reciprocal correlation between the
ability of splenic B cells to present processing-dependent
antigen and the expression of the costimulatory molecule
B7-2. Although the significance of the difference in re-
sponses between time points is questionable, the correla-
tion is repeatable. This experiment does show that the abil-
ity of B cells to present processing-dependent antigen can
be negatively modulated by LPS treatment.
Discussion
Ea6, a T cell clone raised against a peptide derived from
MHC class II Ea chain bound to I-Ab, served as a useful
reagent for studying processing of endogenously synthe-
sized versus exogenously provided antigen for presentation
by MHC class II molecules. The fine specificity of the T
cell epitope was determined. The T cell required a 15-
amino acid peptide, Ea52–66, and was unresponsive to the
longer peptide Ea52–68 unless Ea52–68 was processed.
The Ea52–68 epitope that was created from endogenously
Figure 7. B10.A(3R) mice are tolerant to Ea52–68, but not to Ea52–66, whereas C57BL/6 mice can be primed with both peptides. The proliferative
response of whole lymph node cultures from 3R mice immunized with 30 mg Ea52–68 (A) or Ea52–66 (B). Popliteal lymph node cells from two mice
per experiment were pooled. 4 3 105 cells were cultured with various doses of peptide for 60–72 h before pulsing overnight with 1 mCi/well of [3H]thy-
midine. The data are representative of several experiments. However, the response of mice immunized with Ea52–66 was low, comparable to that of
mice immunized with Ea52–68, in two of five experiments. The response of mice immunized with Ea52–68 was very weak in all experiments. The re-
sponse of B6 mice immunized with Ea52–68 (C) and Ea52–66 (D) is shown. B6 mice responded similarly in response to both peptides in all experi-
ments, although typically, as here, the response to Ea52–66 was greater than the response to Ea52–68.1412 Processing of Autoantigenic Peptides Breaks Self-tolerance
synthesized antigen had already been identified (1). The
evidence that Ea6 could not recognize Ea52–68, despite
the fact that the clone was produced by immunization with
this peptide, came from several sources. First, Ea6 prefers
the shorter peptide by about a factor of 10 when they are
presented by viable APCs (Fig. 2 A). Second, Ea6 responds
to the longer peptide only when it is presented by viable,
processing-competent APCs (Fig. 3 A), and known inhibi-
tors of antigen processing can block the response to the
longer peptide (Fig 4 A). Third, forced recycling with
monoclonal anti–I-Ab antibody produced the epitope for
Ea6 in cells that expressed the Ea chain and I-Ab (3R, 5R,
and B6-107), but not in B6 cells that do not express the Ea
chain. Moreover, only antibodies directed at I-Ab could
produce this effect; the I-E–specific antibodies Y-17 and
14.4.4S (data not shown) were unable to produce the Ea6
epitope, presumably because they forced internalization
only of I-E and not that of I-Ab (Fig. 5). Finally, when B6
mice were used to present purified I-E molecules, they
could produce the epitope recognized by Ea6 (Fig. 6).
Thus, the evidence is overwhelming that the shorter pep-
tide was involved in the epitope recognized by Ea6.
To confirm this, we then immunized both B6 and 5R
mice with the peptides Ea52–68 and Ea52–66. The re-
sults, shown in Fig. 7, demonstrate that 5R mice, as previ-
ously shown (Rudensky, A.Y., and C.A. Janeway, Jr., un-
published data), were tolerant of the Ea52–68 peptide,
even when it was injected in strong adjuvant. Likewise, 5R
mice immunized with Ea52–68 did not mount a signifi-
cant response to Ea52–66. However, 5R mice primed
Figure 8. The ability of Y-Ae to inhibit B10A (3R) T cell responses to
Ea52–66. The proliferative response of popliteal lymph node cells immu-
nized with Ea52–66 and restimulated with Ea52–66 is specifically inhib-
ited with the Y-Ae monoclonal antibody. The mean response in three
separate experiments is shown with the SEM.
Figure 9. LPS stimulation of splenocytes blocks the processing-dependent
presentation of Ea52–68 to Ea6, but does not block the processing-inde-
pendent presentation of Ea52–66 to Ea6 or the processing-independent
presentation of Ea52–68 and Ea52–66 to 1H3.1: (A) The proliferative
response of Ea6 to synthetic Ea peptides presented by B6 splenocytes
that were treated for 18 h with 10 mg/ml LPS. (B) The response of
1H3.1, measured by CTLL assay, to synthetic Ea peptides presented by
B6 LPS blasts. (C) Flow cytometric analysis using Y-Ae to detect binding
of Ea52–66 and Ea52–68 onto I-Ab on LPS or untreated B6 splenocytes.
In C, Y-Ae positive cells represents the mean fluorescence intensity of
cells that stained with Y-Ae. Y-Ae negative cells indicate internal negative
controls, showing that the fluorescence intensity of unstained cells in each
sample was equivalent.1413 Barlow et al.
with the shorter peptide Ea52–66 mounted a vigorous re-
sponse to Ea52–66 as well as a weaker, but still significant,
response to Ea52–68. This is presumably due to the pro-
cessing of the longer Ea52–68 to the shorter Ea52–66 in
the culture. Thus, 5R mice, which express the endoge-
nously processed Ea52–68, are tolerant to it, whereas they
are nontolerant to the shorter peptide Ea52–66. When B6
mice were immunized with either peptide, they showed
vigorous responses to both peptides, although the response
to priming with the shorter peptide gave a stronger re-
sponse, and priming with the longer peptide was recalled
more powerfully with the shorter of the two peptides. This
could reflect some difference in the TCR repertoire in B6
mice, as suggested by the earlier finding that most T cells
raised by immunization of B6 mice with Ea52–68 could
not respond to 5R spleen APCs (Rudensky, A.Y., P. Preston-
Hurlburt, and C.A. Janeway, Jr., unpublished observations).
This response was specifically inhibitable with the Y-Ae
monoclonal antibody, proving its specificity (Fig. 8).
Finally, we used the requirement for processing of
Ea52–68 to examine the relationship between the acquisi-
tion of costimulatory capacity and the ability to take up and
process antigen. This revealed that LPS, used to induce B7
expression on spleen-derived APCs, could inhibit the anti-
gen uptake and processing by such APCs (Figs. 9 and 10).
This reciprocal regulation of costimulatory molecules that
are required for naive T cell activation, and processing of
antigen required for antigen presentation to the TCR, may
be a crucially important defense against autoimmune dis-
ease. APCs take up self-antigens continuously and are espe-
cially likely to do so when stimulated by infection, which
can induce APCs to become costimulatory. Nevertheless,
the ability of an APC to take up and process antigen de-
clines as it becomes B7 positive, perhaps to the point that
the level of autoantigen presented to naive T cells is insuffi-
cient for breaking self-tolerance. Although the evidence in
Figs. 9 and 10 is suggestive, more work clearly needs to be
done to explore this result.
An interesting result that emerged from this work was
the role of the two COOH-terminal amino acids in pre-
sentation of Ea52–66 to the T cell clone Ea6. This clone is
representative of many cloned T cell lines we have pre-
pared over the years that reacted to the immunizing pep-
tide but not to the naturally processed Y-Ae epitope ex-
pressed on 3R and 5R spleen cells. Once we had worked
out that Ea6 is specific for the Ea52–66 peptide, and in
fact ignores the longer, naturally processed peptide Ea52–
68, we realized that most of our cloned lines and hybrido-
mas reacted exclusively to the shorter peptide Ea52–66.
The problem posed by this result is twofold: first, how are
the two COOH-terminal amino acid residues perceived by
the TCR on the majority of our clones and hybridomas,
when they lie at the extreme end of the peptide and are
thus unlikely to contact the TCR at all? Second, why do
most T cells from B6 mice prefer this shorter peptide, even
though immunized with the longer peptide? We will ad-
dress these two questions separately.
Figure 10. Presentation of processing-dependent antigen is diminished
at peak expression of B7. The proliferative response of Ea6 to processing-
independent (A; Ea52–66) and processing-dependent (B; Ea52–68)
epitopes, which were added to APCs at various time points after LPS in-
duction of costimulation. The APCs were treated for 4 h with LPS under
conditions which would deplete adherent dendritic cells and macrophages.
The APCs were washed and peptide was added immediately (4 h) or after
reculture until the time point indicated (8 h). APCs were irradiated immedi-
ately before addition of peptide. The peptide was pulsed onto the APCs
for 2 h and then the unbound peptide was washed away and T cells were
added. Error bars show the SEM calculated on Cricket Graph. (C) Flow cy-
tometric analysis B7.2 (09272D; PharMingen, San Diego, CA) expression
after treatment with LPS in order to induce costimulatory molecule expres-
sion. Splenic APCs were cultured in flasks for 4 h in the presence (LPS) or
absence (none) of LPS. The cells were then harvested (this procedure should
have removed dendritic cells and macrophages due to plastic adherence),
washed, and recultured at 378C for various time points before staining (8
and 24 h), or stained immediately (4 h). No significant differences in Y-Ae
staining were detected on the APCs loaded with Ea52–66 or Ea52–68 at
4, 8, or 24 h after initiation of LPS treatment (data not shown).1414 Processing of Autoantigenic Peptides Breaks Self-tolerance
The processing of peptides for presentation by MHC
class II molecules has been studied by many authors. It is
generally concluded that peptides can range in size from a
minimum of 13 amino acids to a maximum of z25 amino
acids or longer (1, 25, 26). The modal value for peptide
length is 17, exactly the length of Ea52–68. In truncation
studies carried out by many investigators over the years, the
minimal peptide length that can stimulate most T cell
clones and hybrids is 8–9 amino acids, and indeed, the T
cell hybrid 1H3.1 can respond to the minimal peptide
Ea56–64 (AQGALANIA) (Barlow, A.K., R. Medzhitov,
and C.A. Janeway, Jr., data not shown). Nonetheless, the
TCR on Ea6, and most clones we have derived from im-
munization of B6 mice with Ea52–68, ignores this longer
peptide in favor of the shorter Ea52–66, and can not rec-
ognize the minimal peptide epitope AQGALANIA. Re-
cent studies have demonstrated that the COOH terminus
of a peptide makes contact with the TCR Vb region (21–
23), and thus its structure should contain clues as to the
recognition of the two residues that have to be removed
from the endogenously processed form. However, the
TCR-b chains of Ea6 and 1H3.1 are both encoded in
Vb6, so it is unlikely that the terminal residues at the very
extreme end of the peptide can make contact with the only
variable residues of the TCR-b chain, those encoded in
the CDR3 region. We are planning to make b chain–only
transgenic mice from Ea6 and 1H3.1 in order to attempt
to resolve this mystery (3).
The second mystery is why most of the T cell lines and
clones we have analyzed appear to prefer the shorter pep-
tide, as they are unresponsive to 5R spleen cells that
present the naturally processed epitope known to consist
primarily of the 17-amino acid peptide Ea52–68. There
are two possibilities to explain this. The first is that the
shorter peptide has a higher affinity for the I-Ab molecule
than the longer peptide, as suggested by its greater immu-
nogenicity in B6 mice (Fig. 7 B) and its greater potency in
eliciting proliferative responses from T cell clones (Fig. 2).
However, the T cell hybrid, 1H3.1, does not distinguish
these peptides on a molar basis, so the avidity for I-Ab is
probably not the explanation for this difference. The sec-
ond possibility is based on our recent finding that the
MHC class II–specific repertoire is selected on the basis of
recognition of self-peptide–self-MHC class II complexes
during its development in the thymus (3, 24). The self-
peptide repertoire affects both positive and negative in-
trathymic selection, with the main effect being on positive
selection. We hypothesize that there is a ligand in the B6
thymus that more closely resembles the Ea52–66–I-Ab
complex than the Ea52–68–I-Ab complex, and that this
ligand selects a majority of T cells that favor recognition of
the former over the latter complex. Evidence for this being
true comes from the ability of Y-Ae treatment of newborn
B6 mice, which are conventionally thought to lack the Y-Ae
epitope altogether, to inhibit development of T cells spe-
cific for the Ea52–68 and, by inference, Ea52–66 specific
cells as well (Rudensky, A.Y., and C.A. Janeway, Jr., un-
published observations). Now that we have analyzed the
nature of the difference between these two cloned T cell
lines, one of which shows an absolute preference for the
shorter peptide, whereas the other can not distinguish pep-
tide length, we are in the process of preparing TCR trans-
genic mice to analyze selection both in B6 and in I-E1
mice. We predict that the Ea6 TCR will show positive se-
lection in B6 and 5R mice, and we have already observed
profound deletion of the 1H3.1 TCR when it is bred to
5R mice.2
In summary, we have deduced the specificity of two
cloned T cell lines, Ea6 and 1H3.1, and shown them to
differ by the two COOH-terminal amino acids (2KA) of
the peptide Ea52–68. The origin of the differences in rec-
ognition by these two clones remains to be determined by
further studies, perhaps using immunization of single TCR
chain transgenic mice. As the phenotype of Ea6-like
clones appears to be dominant in mice primed with the
peptide Ea52–68, it remains to be determined whether this
is due to events occurring in the thymus before the immu-
nization event. However, this seems likely to be the case
(3, 24). Finally, we have used this system to infer that co-
stimulation is regulated reciprocally with the ability to take
up and process antigen for potentially autoreactive T cells.
This may be yet another mechanism to avoid the induction
of autoimmune responses.
2Viret, C., H. Ramaswamy, D.B. Sant’Angelo, and C.A. Janeway, Jr.,
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